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hTATE-OF-THE-ART PAPER191The Controversial History of Dynamic LV Outflow Tract Obstructionarry J. Maron, Martin S. Maron, E. Douglas Wigle, Eugene Braunwald
ynamic obstruction to left ventricular (LV) outflow was recognized with the earliest clinical
escriptions of hypertrophic cardiomyopathy (HCM) 50 years ago. Maron and colleagues
eview how the clinical significance of this obstruction, or even its reality, has been
ontroversial. Recent studies showing improved outcomes and symptoms once the obstruction
s removed appear to have definitively resolved the controversy. These data also underscore
he important principle that heart failure due to LV outflow obstruction in HCM is
echanically reversible and amenable to septal reduction therapy.TATE-OF-THE-ART PAPER201Genetic Testing for Hypertrophic Cardiomyopathy~ 10% Myofilament 
Gene +
Sigmoidal     
HCM              
40 - 50%
Reverse curve 
HCM              
30 - 40%
~ 80% Myofilament 
Gene +
Apical                  
HCM                 
~ 10% 
~ 30% Myofilament
Gene +
Neutral           
HCM             
~ 10%
~ 40% Myofilament
Gene +. Martijn Bos, Jeffrey A. Towbin, Michael J. Ackerman
ver the last 2 decades the pathogenic basis for hypertrophic cardiomyopathy (HCM) has
een investigated extensively. There is a growing amount of data from genotype-phenotype
orrelation studies. Genetic tests for HCM are now commercially available. Bos and
olleagues provide this review to help the modern-day cardiologist understand the diagnostic,
rognostic, and therapeutic implications of HCM genetic testing, along with guidance on
ho should be tested.TATE-OF-THE-ART PAPER212Clues to Understanding Dynamic LV Obstruction From Doppler Velocity Tracingsark V. Sherrid, Omar Wever-Pinzon, Ajay Shah, Farooq A. Chaudhry
herrid and colleagues reveal how the shape of the Doppler velocity tracings can provide
nsights into the physiology of obstructive hypertrophic cardiomyopathy. Inflection points on
he tracing represent time points when there is a change in the rate of increase in the velocity
f the blood transiting the left ventricular (LV) outflow tract. These inflections are caused by
he amplifying nature of obstruction and the sudden imposition of afterload in midsystole.
his dynamic systolic dysfunction, demonstrated on the Doppler curves, may contribute to
eart failure symptoms and adverse outcomes.(continued on page A-20)
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aLINICAL RESEARCH220CMR Reveals Several Patterns of LV Hypertrophy in HCM Patientsartin S. Maron, Barry J. Maron, Caitlin Harrigan, Jacki Buros, C. Michael Gibson, Iacopo Olivotto,
eah Biller, John R. Lesser, James E. Udelson, Warren J. Manning, Evan Appelbaum
aron and colleagues used cardiovascular magnetic resonance (CMR) imaging to assess
hether hypertrophic cardiomyopathy (HCM) is a diffuse or localized myocardial process.
MR was performed in HCM patients and the presence of hypertrophy (wall thickness 15
m) was assessed in each of the 16 cardiac segments. LV hypertrophy was focal (involving
2 segments) in 12%, intermediate (3 to 7 segments) in 34%, and diffuse (8 segments) in
4% of subjects. The number of involved segments correlated with New York Heart
ssociation functional class and outflow tract obstruction. Patients with HCM can haveocalized or diffuse cardiac involvement.LINICAL RESEARCH229Patients With HCM but a Normal ECG May Have a Less Severe Phenotypehristopher J. McLeod, Michael J. Ackerman, Rick A. Nishimura, A. Jamil Tajik, Bernard J. Gersh,
teve R. Ommen
cLeod and colleagues studied the outcomes of patients with hypertrophic
ardiomyopathy (HCM) who had a normal 12-lead electrocardiogram (ECG).
CM was defined echocardiographically, and approximately 6% of patients had
ormal ECGs. Compared with HCM patients with abnormal ECGs, those with a
ormal ECG had less symptoms and less septal wall thickening, and were less likely
o require surgical myectomy or implantable cardioverter-defibrillator insertion. No
atients with a normal ECG at presentation experienced a cardiac death during
ollow-up. Almost 6% of patients with HCM had a normal ECG at the time of
iagnosis; these patients appear to have a less severe phenotype of the disease.LINICAL RESEARCH234Prognosis for Asymptomatic HCM Patients Depends on LVOT Gradientaul Sorajja, Rick A. Nishimura, Bernard J. Gersh, Joseph A. Dearani, David O. Hodge,
eather J. Wiste, Steve R. Ommen
orajja and colleagues evaluated the long-term outcome of patients with minimally
ymptomatic, obstructive hypertrophic cardiomyopathy (HCM). Enrolled patients had
nexplained wall thickness 15 mm and obstruction, defined as systolic anterior motion of
he mitral valve apparatus and a subaortic Doppler velocity 2.7 m/s at rest or 3.5 m/s
ith provocation. Over 9 years of follow-up, these subjects with asymptomatic HCM had
nly a slight excess mortality compared to a healthy population. However, there was
ignificantly reduced survival in those with a Doppler peak velocity 4 m/s. Patients with
bstructive HCM with minimally elevated left ventricular outflow tract (LVOT) velocities
nd mild or no symptoms have good prognosis.(continued on page A-21)
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ELINICAL RESEARCH242Delayed Enhancement on CMR Correlates With Abnormal Histology in HCM Patientseborah H. Kwon, Nicholas G. Smedira, E. Rene Rodriguez, Carmela Tan, Randolph Setser,
aran Thamilarasan, Bruce W. Lytle, Harry M. Lever, Milind Y. Desai
he etiology of myocardial scarring in hypertrophic cardiomyopathy (HCM) patients is
ebated. Kwon and colleagues studied the association between basal interventricular septal
hickness, myocardial scarring, small intramural coronary arteriole dysplasia (SICAD)
demonstrated by histopathology after surgical myectomy), and ventricular tachyarrhythmias
VTs). SICAD and scar were seen in 75% and 63% of patients, respectively. Patients with
asal septal scar on cardiac magnetic resonance (CMR) had higher VT frequency. There is a
trong association between the degree of SICAD, myocardial scarring, and VT.LINICAL RESEARCH250Risk Factors for Poor Outcomes in Pediatric Patients With HCMamie A. Decker, Joseph W. Rossano, E. O’Brian Smith, Bryan Cannon, Sarah K. Clunie, Corey Gates,
ohn L. Jefferies, Jeffrey J. Kim, Jack F. Price, William J. Dreyer, Jeffrey A. Towbin, Susan W. Denfield
ecker and colleagues reviewed the outcomes of pediatric patients with hypertrophic
ardiomyopathy (HCM) to assess whether the risk factors for sudden cardiac death (SCD)
re similar in children and adults. A primary end point (death or transplantation) occurred in
1% of patients. No single or multiple risk factors were predictive of SCD. Extreme left
entricular hypertrophy (z-score 6) and an abnormal blood pressure response to exercise
ere predictive of non-SCD. In this study of pediatric patients with HCM, non-SCD or
ransplant were at least as common as SCD.LINICAL RESEARCH255HCM Patients Have Increased Aortic Stiffnesshananya Boonyasirinant, Prabhakar Rajiah, Randolph M. Setser, Michael L. Lieber, Harry M. Lever,
ilind Y. Desai, Scott D. Flamm
oonyasirinant and colleagues used cardiac magnetic resonance (CMR) imaging to measure
ortic stiffness in patients with hypertrophic cardiomyopathy (HCM). The pulse wave velocity
PWV) was calculated as the time delay from the start of increased systolic velocity in the
escending aorta compared to the ascending aorta divided by the distance between the 2
oints. PWV was significantly higher in HCM subjects compared with controls and was
igher in HCM patients with myocardial fibrosis than in those without. Further studies are
eeded to determine the pathophysiology and clinical importance of this finding.
ditorial Comment: Harald P. Kühl, p. 263(continued on page A-24)
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rEWS FROM THE NHLBI265The Extramural Cardiovascular Divisions of NHLBI: An Invited Commentaryichael S. Lauer, Sonia I. Skarlatos, Diane E. Bild
he National Heart, Lung, and Blood Institute (NHLBI) Strategic Plan describes an
mbitious agenda in cardiovascular disease research, with most of it implemented via grants
nd contracts to extramural scientists. NHLBI program scientists work to initiate, catalyze,
valuate, and oversee cardiovascular research efforts. This article by Lauer and colleagues
escribes the responsibilities of the different divisions and branches involved in cardiovascular
esearch.
